Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

|Videos|February 3, 2022

MRD and Value-Based Care Models

Dr Patel describes the importance of MRD in value-based care models.

Episodes in this series

EP. 1 Explaining Molecular Residual Disease

EP. 1 Explaining Molecular Residual Disease

EP. 2 The Evolution of Circulating Tumor DNA in Oncology

EP. 2 The Evolution of Circulating Tumor DNA in Oncology

EP. 3 MRD Assessments

EP. 3 MRD Assessments

EP. 4 MRD Results and Guiding Treatment Decisions

EP. 4 MRD Results and Guiding Treatment Decisions

EP. 5 MRD and Value-Based Care Models

EP. 5 MRD and Value-Based Care Models

EP. 6 Supporting MRD Availability

EP. 6 Supporting MRD Availability

EP. 7 INSPIRE and IMvigor011 Trials

EP. 7 INSPIRE and IMvigor011 Trials

EP. 8 Potential Changes for MRD in the Future

EP. 8 Potential Changes for MRD in the Future

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Dr Irina Murakhovskaya | Image Credit: Montefiore Einstein

ENERGY Trial Shows Early Fatigue Benefit With Nipocalimab in wAIHA: Irina Murakhovskaya, MD

ByBrooke McCormick,Irina Murakhovskaya, MD

June 26th 2026

CRC animation | Image Credit: Thipphaphone - stock.adobe.com

Early-Life, Parental Factors May Help Explain Rising Early-Onset CRC Rates

ByBrooke McCormick

June 26th 2026

This segment explores how emerging data on oral selective estrogen receptor degraders are being applied in clinical practice for hormone receptor–positive, HER2-negative metastatic breast cancer.

HR-Positive Breast Cancer: Clinical Use of Oral SERDs in Combination vs Monotherapy

ByAdam Brufsky, MD, PhD,Hope Rugo, MD,Dr. Mabel Mardones, MD,Ms. Lori Brisbin, MS, MLS Healthcare Law,Dr. Lisa Raff, PharmD

Published: June 26th 2026 | Updated: June 26th 2026

This segment introduces the evolving treatment landscape in hormone receptor–positive, HER2-negative metastatic breast cancer, with a focus on the growing clinical relevance of ESR1 mutations.

HR-Positive Breast Cancer: Evolving Role of ESR1 Mutations in Endocrine Resistance

ByAdam Brufsky, MD, PhD,Hope Rugo, MD,Dr. Mabel Mardones, MD,Ms. Lori Brisbin, MS, MLS Healthcare Law,Dr. Lisa Raff, PharmD

Published: June 26th 2026 | Updated: June 26th 2026

Stamp that says "FDA Approved" in blue ink. | Image Credit: Surendra - stock.adobe.com

FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer

ByElla Hohmann, MS

June 25th 2026

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

National HIV Testing Day Highlights Expanding PrEP, PEP Access, Persistent Barriers

Treatment Burden, End-of-Life Symptom Gaps in Multiple Myeloma

ATTR-CM Incidence, Prevalence Rose Sharply in the US

Health Equity & Access Weekly Roundup: June 26, 2026